PICO Portalanswers from OpenAlex & ORCID
Lucjan Wyrwicz
ResearcherPublications, citations & collaboration network
Lucjan Wyrwicz is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Lucjan Wyrwicz have?
PICO Portalindexed works
Lucjan Wyrwicz has 287 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Lucjan Wyrwicz have?
PICO Portalcitation count
Lucjan Wyrwicz has 16,157 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Lucjan Wyrwicz?
PICO Portalh-index
Lucjan Wyrwicz has an h-index of 51 in OpenAlex.
What is the i10-index of Lucjan Wyrwicz?
PICO Portali10-index
Lucjan Wyrwicz has an i10-index of 126 in OpenAlex.
What is the ORCID of Lucjan Wyrwicz?
PICO Portalorcid
The ORCID for Lucjan Wyrwicz is on the source record.
What is the OpenAlex record for Lucjan Wyrwicz?
PICO Portalopenalex
The OpenAlex for Lucjan Wyrwicz is on the source record.
What are the most-cited papers on Lucjan Wyrwicz?
PICO Portalmost cited works
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Yuichiro� Doki, Jaffer A. Ajani, Ken Kato, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih‐Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Sandra A. Ostoich, Hye R. Kim, Masaki Ueno, Wasat Mansoor, Wen‐Chi Yang, Tianshu Liu, John Bridgewater, Tomoki Makino, Ioannis Xynos, Xuan Liu, Ming Lei, Kaoru Kondo, Apurva Patel, Joseph Gricar, Ian Chau, Yuko Kitagawa, Doki, Yuichiro, Jaffer A. Ajani, Ken Kato, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Hsu, Chih Hung, Antoine Adenis, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Sandra A. Ostoich, Hye R. Kim, Masaki Ueno, Wasat Mansoor, Yang, Wen Chi, Tianshu Liu, John Bridgewater, Tomoki Makino, Ioannis Xynos, Xuan Liu, Ming Lei, Kaoru Kondo, Apurva Patel, Joseph Gricar, Ian Chau, Yuko Kitagawa
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
Gerald W. Prager, Julien Taı̈eb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Élez, Felipe Melo Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Pápai, Pierre-Guillaume Poureau, Gábor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik Paul Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loïck Vidot, Josep Tabernero
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
Jianming Xu, Ken Kato, Eric Raymond, Richard Hubner, Yongqian Shu, Yueyin Pan, Sook Ryun Park, Lu Ping, Yi Jiang, Jingdong Zhang, Xiaohong Wu, Yuanhu Yao, Lin Shen, Takashi Kojima, Evgeny Gotovkin, Ryu Ishihara, Lucjan Wyrwicz, Eric Van Cutsem, Paula Jiménez‐Fonseca, Chen‐Yuan Lin, Lei Wang, Jingwen Shi, Liyun Li, Harry H. Yoon